Weighing the Evidence: A Pharmacy Approach to Stroke Prevention in Obese Patients with Non-Valvular Atrial Fibrillation

In this CME Outfitters virtual symposium, expert faculty review key aspects of the prescribing information, guidelines, and recently published safety and efficacy data for DOACs and warfarin in order to enable pharmacists and other clinicians to support evidence-based therapeutic treatment decisions in obese patients with NVAF.

At the end of this CE activity, participants should be able to:
-Assess existing guidelines and U.S. prescribing information for use of DOACs and warfarin to prevent stroke in obese patients with NVAF.
-Evaluate safety and efficacy data for DOACs and warfarin in obese patients with NVAF.
-Counsel obese patients with NVAF on risks and benefits of DOACs and warfarin to optimize adherence and health outcomes.

The following learning objectives pertain only to those requesting CNE or CPE credit:
-Assess existing guidelines and U.S. prescribing information for use of DOACs and warfarin to prevent stroke in obese patients with NVAF.
-Evaluate safety and efficacy data for DOACs and warfarin in obese patients with NVAF.
-Counsel obese patients with NVAF on risks and benefits of DOACs and warfarin to optimize adherence and health outcomes.